1 Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. New Engl J Med. 2020;383:1920–31.
doi:10.1056/nejmoa2022483.
2 Mulligan M J, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lokhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–93.
3 Houseley J, Tollervey D. The Many Pathways of RNA Degradation. Cell. 2009;136:763–76.
4 Pardi N, Hogan M J, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–79.
5 Chen N, Xia P, Li S, Zhang T, Wang TT, Zhu J. RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life. 2017;69:297–304.
6 Jia J, Zhang Y, Xin Y, Jiang C, Yan B, Zhai S. Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy. Frontiers Oncol. 2018;8:404.
7 Khalil IA, Younis MA, Kimura S, Harashima H. Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids. Biological Pharm Bulletin. 2020;43:584–95.
8 Rijkers GT, Weterings N, Obregon-Henao A, Lepoder M, Dutt T, van Overveld FJ, Henao-Tamayo M. Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines. 2021;9:848.
9 Chahal JS, Fang, T, Woodham AW, Khan OF, Ling J, Anderson DG, Ploegh HK. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci Rep. 2017;7:252.
10 Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K, et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020;369:1501–5.
11 Heyward JT, Klimas RA, Stapp MD, Obijeski JF. The rapid concentration and purification of influenza virus from allantoic fluid. Arch Virol. 1977;55:107–19.
12 McLean KA, Goldin S, Nannei C, Sparrow E, Torelli G. The 2015 global production capacity of seasonal and pandemic influenza vaccine. Vaccine. 2016;34:5410–13.
13 Boerner LK. The Flu Shot and the Egg. Acs Central Sci. 2020;6:89–92.
14 Divino V, Krishnarajah G, Pelton SI, Mould-Quevedo J, Anupindi VR, DeKoven M, Postma MJ. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season. Vaccine. 2020;38:6334–43.
15 McNeil MM. Vaccine-Associated Anaphylaxis. Curr Treat Options Allergy. 2019;6:297–308.
16 Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract. 2021;9:3546–67.
doi:10.1016/j.jaip.2021.06.006.
17 Wu F, Zhao S, Yu B, Chen Y, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–69 (2020).
18 Corbett KS, Edwards DS, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–71.
20 WHO. WHO COVID-19 weekly report. 2020.
21 Baden LR, Hana M, Sahly E, Essink B, Kotloff K, Frey S, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New Engl J Med. 2020;384:403–16.
22 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New Engl J Med. 2020;383:2603–15.
23 Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New Engl J Med. 2021;384:1412–23.
24 Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New Engl J Med. 2021;385:585–94.
25 Sanderson K. COVID vaccines protect against Delta, but their effectiveness wanes. Nature. 2021. doi:10.1038/d41586-021-02261-8.
26 Pichla-Gollon SL, Lin SW, Hensley SE, Lasaro MO, Herkenhoff-Haut L, Drinker M, et al. Effect of Preexisting Immunity on an Adenovirus Vaccine Vector: In Vitro Neutralization Assays Fail To Predict Inhibition by Antiviral Antibody In Vivo. J Virol. 2009;83:5567–73.
27 Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA; 2021:326:1210-2.
28 Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA. Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Adv Drug Deliver Rev. 2021;170;113–41.
29 Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021;326:1390–9.
30 Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New Engl J Med. 2021;385:1761–73.
doi:10.1056/nejmoa2110345.
31 Keesing F, Belden LK, Daszak P, Dobson A, Harvell CD, Holt RD, et al. Impacts of biodiversity on the emergence and transmission of infectious diseases. Nature. 2010;468:647–52.
32 Gibb R, Redding DW, Chin KQ, Donnelly CA, Blackburn TM, Newbold T, Jones KE. Zoonotic host diversity increases in human-dominated ecosystems. Nature. 2020;584;398–402.
33 Awasthi S, Hook LM, Pardi N, Wang F, Myles A, Cancro MP, et al. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol. 2019;4:eaaw7083.
34 Aliprantis AO, Shaw CA, Griffin P, Farinola N, Railkar RA, Cao X, et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum Vacc Immunother. 2020;17:1–14.
35 Meyer M, Huang E, Yuzhakov O, Ramanathan P, Ciaramella G, Bukreyev A. Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease. J Infect Dis. 2017;217:451–5.
36 Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390:1511–20.
37 Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021;28:117–29.
38 Pattnaik A, Sahoo B R, Pattnaik AK. Current Status of Zika Virus Vaccines: Successes and Challenges. Vaccines. 2020;8:266.